7. Introducing Lepodisiran: The Experimental Drug

Lepodisiran, created by Eli Lilly, represents a major innovation in genetic cholesterol treatment.
This experimental drug uses RNA interference technology to silence the LPA gene, which is directly responsible for Lp(a) production. By interrupting the gene’s activity, lepodisiran can almost completely eliminate Lp(a) from the bloodstream in early clinical trials. These results have generated significant excitement in the cardiology community. Read more about the trial at The New England Journal of Medicine.